The FDA has granted Fast Track designation to the investigational antibody-drug conjugate (ADC) SIM0505 for the treatment of women with platinum-resistant ovarian cancer. The designation adds SIM0505 ...

Rising cancer prevalence, demand for precise dosage, expanding tele-oncology networks AI Tele-Oncology Radiation Dose ...

The FDA and Corbus Pharmaceuticals Holdings, Inc., have agreed on second-line registrational study designs evaluating CRB-701 ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ...

Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...

FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential ...

GLIX1 is an orally available, first-in-class small molecule designed to activate TET2 and drive tumor-selective DNA damage. By restoring TET2 activity, GLIX1 induces DNA damage selectively in cancer ...

In the announcement, FDA Commissioner Mackary said, “Bayesian methodologies help address two of the biggest problems of drug ...

What was once 25 treatments over five weeks can now often be delivered in 16 treatments, or even as few as five fractions.

The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor ...

Detailed price information for Adagene Inc ADR (ADAG-Q) from The Globe and Mail including charting and trades.

Drug resistance remains a central barrier to durable responses across cancer therapies, spanning targeted agents, cytotoxic chemotherapy, endocrine ...